Provectus Biopharmaceuticals, Inc. (PVCT) — 8-K Filings

8-K Filings (17)

• Provectus Biopharmaceuticals Files 8-K on Shareholder Vote Matters — Jun 20, 2025 Risk: low
  On June 18, 2025, Provectus Biopharmaceuticals, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The filing was made pu
• Provectus Biopharmaceuticals Files 8-K — Jun 18, 2025 Risk: low
  On June 18, 2025, Provectus Biopharmaceuticals, Inc. filed an 8-K report. The filing primarily consists of financial statements and exhibits, with no specific m
• Provectus Biopharmaceuticals Changes Auditors — Apr 16, 2025 Risk: low
  On April 15, 2025, Provectus Biopharmaceuticals, Inc. filed an 8-K report to disclose a change in its certifying accountant. The company has appointed BDO USA,
• Provectus Biopharma Reports Material Agreement and Equity Sales — Jan 22, 2025 Risk: medium
  On January 15, 2025, Provectus Biopharmaceuticals, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also r
• Provectus Biopharmaceuticals Enters Material Definitive Agreement — Dec 26, 2024 Risk: medium
  On December 20, 2024, Provectus Biopharmaceuticals, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal
• Provectus Biopharmaceuticals Files 8-K — Dec 11, 2024 Risk: low
  On December 5, 2024, Provectus Biopharmaceuticals, Inc. filed an 8-K report detailing other events and financial statements. The company, incorporated in Delawa
• Provectus Biopharma Files 8-K on Director/Officer Changes — Dec 5, 2024 Risk: medium
  On December 2, 2024, Provectus Biopharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing i
• Provectus Biopharmaceuticals Files 8-K — Nov 14, 2024 Risk: low
  On November 14, 2024, PROVECTUS BIOPHARMACEUTICALS, INC. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements an
• Provectus Biopharma Appoints New Director and CMO — Aug 19, 2024 Risk: medium
  On August 14, 2024, Provectus Biopharmaceuticals, Inc. announced changes in its board of directors and executive compensation. Specifically, the company elected
• Provectus Biopharm Enters Material Agreement, Reports Equity Sales — Jul 17, 2024 Risk: medium
  On July 11, 2024, Provectus Biopharmaceuticals, Inc. entered into a material definitive agreement and incurred a direct financial obligation. The company also r
• Provectus Biopharmaceuticals Files 8-K with Material Agreement — Jun 25, 2024 Risk: medium
  On June 21, 2024, Provectus Biopharmaceuticals, Inc. entered into a material definitive agreement. The company also amended its Articles of Incorporation and fi
• Provectus Biopharmaceuticals Files 8-K on Security Holder Vote — Jun 21, 2024 Risk: low
  On June 20, 2024, Provectus Biopharmaceuticals, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The filing does not co
• Provectus Biopharmaceuticals Director Departs — Apr 16, 2024 Risk: low
  On April 10, 2024, Provectus Biopharmaceuticals, Inc. announced the departure of Dr. Craig M. Cordola from its Board of Directors. The company also reported on
• Provectus Biopharmaceuticals Files 8-K — Mar 27, 2024 Risk: medium
  On March 21, 2024, Provectus Biopharmaceuticals, Inc. entered into a material definitive agreement. The company also disclosed information related to Regulation
• Provectus Biopharmaceuticals Appoints New Chief Medical Officer — Mar 26, 2024 Risk: medium
  On March 25, 2024, Provectus Biopharmaceuticals, Inc. announced the appointment of Dr. Craig M. Bial as Chief Medical Officer. Dr. Bial brings extensive experie
• PROVECTUS BIOPHARMACEUTICALS Files Routine 8-K Disclosure — Feb 22, 2024 Risk: low
  PROVECTUS BIOPHARMACEUTICALS, INC. filed an 8-K on February 22, 2024, to disclose information under Regulation FD and to include financial statements and exhibi
• PROVECTUS BIOPHARMACEUTICALS Files 8-K on Feb 15 — Feb 15, 2024 Risk: low
  PROVECTUS BIOPHARMACEUTICALS, INC. filed an 8-K on February 15, 2024, under Regulation FD Disclosure and Financial Statements and Exhibits. The filing indicates

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX